Switch theme
Sign up to access all valuation multiples
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.
1973
n/a
LTM Revenue $105M
LTM EBITDA $3.5M
$949M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hanall Biopharma has a last 12-month revenue (LTM) of $105M and a last 12-month EBITDA of $3.5M.
In the most recent fiscal year, Hanall Biopharma achieved revenue of $101M and an EBITDA of $2.2M.
Hanall Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hanall Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $105M | XXX | $101M | XXX | XXX | XXX |
| Gross Profit | $56.7M | XXX | $53.3M | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $3.5M | XXX | $2.2M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| EBIT | $1.2M | XXX | $0.2M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | 0% | XXX | XXX | XXX |
| Net Profit | $2.6M | XXX | -$1.3M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hanall Biopharma's stock price is KRW 25900 (or $19).
Hanall Biopharma has current market cap of KRW 1.32T (or $957M), and EV of KRW 1.31T (or $949M).
See Hanall Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $949M | $957M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hanall Biopharma has market cap of $957M and EV of $949M.
Hanall Biopharma's trades at 9.4x EV/Revenue multiple, and 433.8x EV/EBITDA.
Equity research analysts estimate Hanall Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hanall Biopharma has a P/E ratio of 370.5x.
See valuation multiples for Hanall Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $957M | XXX | $957M | XXX | XXX | XXX |
| EV (current) | $949M | XXX | $949M | XXX | XXX | XXX |
| EV/Revenue | 9.0x | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBITDA | 268.5x | XXX | 433.8x | XXX | XXX | XXX |
| EV/EBIT | 805.1x | XXX | 5662.8x | XXX | XXX | XXX |
| EV/Gross Profit | 16.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 370.5x | XXX | -729.7x | XXX | XXX | XXX |
| EV/FCF | 365.2x | XXX | -95.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHanall Biopharma's last 12 month revenue growth is 12%
Hanall Biopharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hanall Biopharma's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hanall Biopharma's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hanall Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Growth | 92% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hanall Biopharma acquired XXX companies to date.
Last acquisition by Hanall Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Hanall Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hanall Biopharma founded? | Hanall Biopharma was founded in 1973. |
| Where is Hanall Biopharma headquartered? | Hanall Biopharma is headquartered in South Korea. |
| Who is the CEO of Hanall Biopharma? | Hanall Biopharma's CEO is Mr. Seung-Guk Park. |
| Is Hanall Biopharma publicy listed? | Yes, Hanall Biopharma is a public company listed on KRX. |
| What is the stock symbol of Hanall Biopharma? | Hanall Biopharma trades under 009420 ticker. |
| When did Hanall Biopharma go public? | Hanall Biopharma went public in 1989. |
| Who are competitors of Hanall Biopharma? | Similar companies to Hanall Biopharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hanall Biopharma? | Hanall Biopharma's current market cap is $957M |
| What is the current revenue of Hanall Biopharma? | Hanall Biopharma's last 12 months revenue is $105M. |
| What is the current revenue growth of Hanall Biopharma? | Hanall Biopharma revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Hanall Biopharma? | Current revenue multiple of Hanall Biopharma is 9.0x. |
| Is Hanall Biopharma profitable? | Yes, Hanall Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hanall Biopharma? | Hanall Biopharma's last 12 months EBITDA is $3.5M. |
| What is Hanall Biopharma's EBITDA margin? | Hanall Biopharma's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Hanall Biopharma? | Current EBITDA multiple of Hanall Biopharma is 268.5x. |
| What is the current FCF of Hanall Biopharma? | Hanall Biopharma's last 12 months FCF is $2.6M. |
| What is Hanall Biopharma's FCF margin? | Hanall Biopharma's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Hanall Biopharma? | Current FCF multiple of Hanall Biopharma is 365.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
